
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc has exhibited consistent growth in its EsoGuard testing volume, processing 2,841 tests in Q3, marking an increase from previous quarters, which indicates a positive trajectory in product adoption. This growth, alongside its diverse pipeline of medical technologies, positions the company favorably within the medical technology sector, highlighting substantial upside potential relative to its current share price. Furthermore, the opportunity for significant expansion in 2025 and 2026 for its products underscores the attractive valuation of PAVmed, balancing its inherent risks with the promise of future revenue growth.
Bears say
PAVmed Inc has reported a pro forma net loss of $0.8 million, which is inconsistent with previous estimates and highlights ongoing financial challenges, including a negative earnings per share (EPS) of $(0.05). The company has also experienced a decline in the number of EsoGuard tests processed, dropping from 3,034 in Q1 to 2,756 in Q2, indicating potential issues with demand or market penetration for its diagnostic products. Furthermore, with early-stage commercialization efforts and significant risks regarding regulatory approvals, reimbursement, and competition, PAVmed's ability to generate substantial revenue and sustain growth in its product pipeline remains uncertain, ultimately contributing to a negative outlook for its stock.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares